Detalles de la búsqueda
1.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 386(19): 1793-1803, 2022 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35544387
2.
Antiviral Activity of Lenacapavir Against HIV-2 Isolates and Drug-resistant HIV-2 Mutants.
J Infect Dis
; 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38060982
3.
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
J Infect Dis
; 226(11): 1985-1991, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36082606
4.
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
J Med Virol
; 91(12): 2188-2194, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31389026
5.
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
J Infect Dis
; 215(6): 920-927, 2017 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453836
6.
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
HIV Clin Trials
; 17(2): 78-87, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26892863
7.
Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Antimicrob Agents Chemother
; 59(10): 5917-24, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26149983
8.
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
J Infect Dis
; 207 Suppl 2: S70-7, 2013 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23687292
9.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother
; 57(6): 2654-63, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529738
10.
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Antimicrob Agents Chemother
; 54(6): 2345-53, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20308382
11.
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
AIDS
; 21(6): 761-3, 2007 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-17413698
12.
The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Antivir Chem Chemother
; 18(6): 307-16, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-18320935
13.
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
PLoS One
; 12(2): e0172206, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28212411
14.
The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.
Antivir Ther
; 11(2): 155-63, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16640096
15.
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Nucleosides Nucleotides Nucleic Acids
; 25(1): 89-107, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16440988
16.
High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Antiviral Res
; 132: 50-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27208653
17.
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.
AIDS
; 19(16): 1751-60, 2005 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-16227782
18.
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Antivir Ther
; 10(2): 343-8, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15865229
19.
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
AIDS
; 16(9): 1227-35, 2002 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-12045487
20.
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral Res
; 93(2): 288-296, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197635